Bristol-myers Squibb Compnay

Lan-Ying Qin

Zheming Ruan

Brian E Fink

Dharmpal S Dodd

Yufen Zhao

Lalgudi S Harikrishnan

Muthoni G Kamau

Robert J Cherney

Libing Chen

Lyndon A M Cornelius

Steven J Walker

T G Murali Dhar

Michael A Poss

Joseph Anthony Tino

Scott Hunter Watterson

Rajeev S Bhide

Qingjie Liu

David Marcoux

James Aaron Balog

Douglas G Batt

Hai-Yun Xiao

Upender Velaparthi

Qing Shi

Peter Kinam Park

Ashok Vinayak Purandare

Emily Charlotte Cherney

Khehyong Ngu

Hua Gong

Anurag S Srivastava

Hasibur Rahaman

James Neels

Samuel J Bonacorsi, Jr

Jianqing Li

Tg Murali Dhar

Arvind Mathur

Wayne David Vaccaro

Robert Joseph Cherney

Brian Edward Fink

Pravin S Shirude

Lyndon AM Cornelius

TG Murali Dhar

Disclosed are compounds of Formula (I): or stereoisomers, tautomers, or salts thereof, wherein each R is independently H or D. Also disclosed are methods of using such compounds to decrease the levels of IKZF1-4 proteins; and pharmaceutical compositions comprising the compound. The compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Substituted phenyl oxazolone compounds

The present invention is directed to compounds of the formula (I), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders. 

Cyclic dinucleotides as anticancer agents

The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders. 

There are described ROR&#x3b3; modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR&#x3b3; Gamma activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR&#x3b3; Gamma activity, for example, autoimmune and/or inflammatory disorders. 

Heterocyclic sulfones as ROR gamma modulators

Disclosed are compounds of Formula (I) or a salt thereof; wherein: X is N or CH; Qis: (i) Cl, Br, I, &#x2014;CN, &#x2014;CH, or &#x2014;CF; (ii) a 5-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, and thiadiazolyl; (iii) a 6?membered heteroaryl selected from pyridinyl, pyridazinyl, and pyrimidinyl; or (iv) a bicyclic heteroaryl selected from indolyl, pyrrolopyridinyl, pyrazolopyridinyl and benzo[d]oxazolyl; wherein each of said 5-membered, 6-membered, and bicyclic heteroaryl is substituted with zero to 1 Rand zero to 1 R; and R, R, R, R, R, R, R, and Rare defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases. 

Bicyclic heteroaryl amine compounds

Disclosed are compounds of Formula (I); or a salt thereof; wherein Qi is (i) Cl, Br, I, &#x2014;CN, &#x2014;CH, or &#x2014;CF; or (ii) pyrazole, triazole, or pyridinyl, each substituted with R; Qis pyridinyl, indazolyl, isoquinolinyl, or benzo[d]imidazolyl substituted with Rand R; and R, R, and Rare defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases. 

Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors

Growing community of inventors

Plainsboro, NJ, United States of America

Lan-Ying Qin